Diabetic Renal Disease — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for diabetic renal disease. 2 active patents protecting 1 drugs from 1+ originators. First major cliff: 2041. Daily refresh.

1
Approved drugs
2
Active US patents
65/100
Avg vulnerability
—
Annual revenue covered

Originators in Diabetic Renal Disease

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Merck & Co. 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating diabetic renal disease. Each bar = one year. Y-axis scaled to peak year (1 patents).

No expiries in next 15 years.

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Cozaar
LOSARTAN POTASSIUM
 Merck & Co. 2 65 — 2041-10-07

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12156869 Cozaar method of use 75 2041-10-07
11890273 Cozaar formulation 55 2041-10-07

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11890273 Cozaar formulation 55 2041-10-07
12156869 Cozaar method of use 75 2041-10-07

Related